端粒酶是干扰素抗肿瘤的新靶点

端粒酶(telomerase)是一种具有逆转录活性的核糖核蛋白酶.端粒酶的异常活化是细胞永生化和肿瘤形成的关键步骤. 端粒酶活性与细胞周期及细胞凋亡调控密切相关;端粒酶由端粒酶逆转录酶、端粒酶RNA、端粒酶相关蛋白质组成,端粒酶逆转录酶是端粒酶活性的决定性组分.干扰素(interferon)是一种具有抗病毒、抗增殖、抗肿瘤和免疫调节等功能的细胞因子;近年研究表明,干扰素通过相关信号转导途径而调节端粒酶活性,诱导细胞凋亡,为肿瘤的生物治疗提供了新思路;但干扰素与端粒酶活性相关的抗肿瘤机制研究尚不充分. 本文综述干扰素通过调节端粒酶逆转录酶转录因子的表达和相互作用而抑制端粒酶活性、调节细胞周期并诱导细胞凋亡等抗肿瘤作用机制.     

人端粒酶催化亚基基因启动子调控的肿瘤细胞特异表达载体

为获得端粒酶阳性肿瘤细胞特异表达载体用于癌症的基因治疗 ,克隆并构建了人端粒酶催化亚基 (hTERT)基因启动子调控的萤光素酶报告载体 .用脂质体转染法将其分别转染肿瘤细胞和正常细胞 ,检测其在肿瘤细胞和正常细胞中的转录活性 .hTERT启动子在所检测的 4种端粒酶阳性的肿瘤细胞中具有明显的转录活性 ,平均为阳性对照的 4 4 3% ;而在端粒酶阴性的正常人胚肺成纤维细胞中则无明显的转录活性 .提示hTRET启动子的转录活性在端粒酶阳性的肿瘤细胞中明显上调 ,由hTERT启动子构建的载体可能是一种新颖和有前景的肿瘤细胞特异性表达的基因治疗载体     

Pinx1表达与端粒酶活性及肿瘤的关系

Pinx1作为端粒酶抑制剂,也是最近发现的一种新型肿瘤抑制因子.通过对内源性端粒酶抑制基因Pinx1与端粒酶、端粒相关蛋白在肿瘤中的表达以及Pinx1在肿瘤演进过程中的作用及临床意义进行一系列的研究,发现肿瘤中Pinx1表达下降与端粒酶活性增高密切相关,且端粒酶活性增高的程度与肿瘤的预后相关.现对近年来Pinx1基因的最新研究进展,特别是该基因表达与端粒酶活性在肿瘤发生、发展中的作用,作一综述和分析.     

端粒和端粒酶在植物生长发育中的调控作用

端粒对染色体、整个生物基因组,甚至对细胞的稳定都具有重要意义,它的作用的发挥离不开端粒酶的作用.目前端粒研究的核心主要是在动物细胞方面.就植物端粒、端粒酶以及其在植物生长发育中的调节作一概述.     

端粒酶的非端粒保护作用

端粒酶与细胞永生化和肿瘤的发生发展密切相关,过去认为是由于端粒酶保护端粒从而阻止因端粒缩短所导致的细胞凋亡;然而近年来,越来越多证据表明:端粒酶在维持端粒长度之外,还存在着非端粒保护作用。通过对其非端粒保护作用的研究,有助于深入而全面地阐明端粒酶的生物学行为及其作用机理,对于肿瘤等疾病的治疗具有重要意义。本文对端粒酶的非端粒保护作用进行小结。     

端粒酶抑制剂

端粒酶被激活被认为是发生恶性肿瘤的主要因素,其激活及表达程度与肿瘤的发生和转移密切相关,因此端粒酶是肿瘤靶向治疗的理想靶点。研究和开发端粒酶抑制剂将为肿瘤治疗揭开新的篇章。端粒酶全酶复合物有很多可以做抑制剂的靶点,包括hTR(端粒酶RNA成分)、hTERT(端粒酶逆转录催化亚单位)、引物锚定位点、全酶的组装和那些招募端粒酶到端粒的因子。     

鸡的端粒生物学研究

端粒是线性染色体末端的核蛋白"帽子"结构,其长度由端粒酶来维持。端粒对于维持基因组的稳定、防止细胞衰老和肿瘤发生具有重要的作用。鸡是遗传和发育研究的经典模式动物,随着鸡基因组学研究的不断深入,鸡的端粒和端粒酶研究取得了很大进展。文章综述了近年来鸡的端粒生物学研究进展,并提出了未来的研究方向。     

端粒和端粒酶与衰老研究

衰老是一种多因素的复合调控过程,表现为染色体端粒长度的改变、DNA损伤、DNA的甲基化和细胞的氧化损伤等,并已形成了许多学说,而端粒学说成为衰老研究的热点之一.对与衰老紧密相关的因素———端粒、端粒酶的结构及其与衰老关系的研究进展进行综述,阐明对端粒—端粒酶的作用将会在抗衰老方面有着十分重要的理论价值及实际意义.     

染色体是如何被端粒和端粒酶保护的?——2009年诺贝尔生理学或医学奖解读

端粒对维持染色体的稳定和延长细胞寿命至关重要,其长度的维持有赖于端粒酶的存在.布莱克本和绍斯塔克发现端粒中的一种独特DNA序列能保护染色体免于退化,格雷德和布莱克本发现了端粒酶及其作用.这些发现揭示了端粒形成和端粒酶保护染色体的机理,3位美国科学家因此荣获2009年诺贝尔生理学或医学奖.     

端粒酶和端粒酶抑制剂研究进展

端粒酶是一种将端粒区的重复序列加到染色体末端的逆转录酶。端粒酶核蛋白复合物包含了两个基本组分:一个催化蛋白亚单位(hTERT)和一个模板RNA(hTR)。早期的研究讨论了端粒酶及其抑制剂与癌症的关系,由于绝大多数癌症多发于老年期,通常伴随着衰老,预计受癌症困扰的人数会在未来不断增加,而端粒酶激活在细胞的永生化及癌变过程中发挥重要作用,有可能成为癌症治疗的新靶点。端粒酶在绝大多数肿瘤细胞中都有表达,而大部分正常的体细胞中无端粒酶的活性。     

An introduction to telomeres and telomerase

It is now more than a dozen years since the enzyme telomerase was discovered, and since that time, key studies have characterized the structural components of the enzyme and the associated telomeric proteins. Since the original discovery of telomerase, a clear association with cancer has been demonstrated. In normal somatic cells the telomeres at the ends of chromosomes shorten with every cell division, whereas in cancer cells telomere length is often maintained by reactivation of the enzyme telomerase. These discoveries have led to the proposal that telomerase expression can be used as a helpful marker for diagnostic and prognostic purposes in humans. Another area of research that has developed as a result of improving knowledge and understanding of the role of telomerase in malignancy is that of cancer therapeutics. This article is an introduction to the field of telomere and telomerase research, with an introduction to recent attempts to develop novel cancer treatments based on telomerase structure and function.     

Preferential extension of short telomeres induced by low extracellular pH

The majority of tumor cells overcome proliferative limit by expressing telomerase. Whether or not telomerase preferentially extends the shortest telomeres is still under debate. When human cancer cells are cultured at neutral pH, telomerase extends telomeres in telomere length-independent manner. However, the microenvironment of tumor is slightly acidic, and it is not yet known how this influences telomerase action. Here, we examine telomere length homeostasis in tumor cells cultured at pHe 6.8. The results indicate that telomerase preferentially extends short telomeres, such that telomere length distribution narrows and telomeres become nearly uniform in size. After growth at pHe 6.8, the expression of telomerase, TRF1, TRF2 and TIN2 decreases, and the abundance of Cajal bodies decreases. Therefore, telomerase are insufficient for extending every telomere and shorter telomeres bearing less shelterin proteins are more accessible for telomerase recruitment. The findings support the ‘protein-counting mechanism’ in which extended and unextended state of telomere is determined by the number of associated shelterin proteins and the abundance of telomerase. Decreased expression of telomerase and preferential extension of short telomeres have important implications for tumor cell viability, and generate a strong rationale for research on telomerase-targeted anti-cancer therapeutics.     

Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity

Telomerase activity is dependent on the expression of 2 main core component genes, hTERT, which encodes the catalytic component and hTR (also called TERC), which encodes the RNA component. The correlation between telomerase activity and carcinogenesis has made this molecule of great interest in cancer research, however in order to fully understand the regulation of telomerase the mechanisms controlling both telomerase genes need to be studied. Some of these mechanisms of regulation have begun to emerge, however many more remain to be deciphered. For many years hTERT has been regarded as the limiting component of telomerase and much of the research in this field has focussed on its regulation, however it was clear from an early stage that hTR expression was also tightly regulated in normal cells and disease. More recently evidence from biochemistry, promoter studies and mouse models has been steadily increasing for a role for hTR as a limiting and essential component for telomerase activity and telomere maintenance. Perhaps the time has come to redefine our view of telomerase regulation. Knowledge of the mechanisms controlling both telomerase genes in normal systems and cancer may aid our understanding of the role of telomerase in carcinogenesis or highlight potential areas for therapeutic intervention. Here we review the essential requirement of hTR for telomere maintenance and telomerase activity in normal tissues and disease and focus on recent advances in our understanding of hTR regulation in relation to hTERT.     

端粒、端粒酶与肿瘤的相关研究进展

端粒是真核细胞染色体末端的DNA序列,在维持染色体的稳定中起着重要的作用。快速生长的细胞通过端粒酶来合成端 粒重复序列以弥补其损耗。在人类恶性肿瘤细胞中,85%以上能检测到端粒酶的活性,使其成为一个几乎普遍的癌标志物,而在大 多数正常体细胞中,端粒酶是阴性的。端粒酶与肿瘤之间的最新研究已经在肿瘤生物学领域开辟了新的途径,可能会彻底改变抗 癌疗法。在这篇文章中,我们将会总结端粒和端粒酶在癌细胞中的作用。随着科技的发展,端粒和端粒酶拥有巨大的潜力,必将能 够为肿瘤的治疗带来更多的方法。     

Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease

Telomerase enzyme is a ribonucleoprotein maintaining the length of the telomeres by adding G-rich repeats to the end of the eukaryotic chromosomes. Normal human somatic cells, cultured in vitro, have a strictly limited proliferative potential undergoing senescence after about 50-70 population doublings. In contrast, most of the tumor cells have unlimited replicative potential. Although the mechanisms of immortalization are not understood completely at a genetic level, the key role of the telomere/telomerase system in the process is clear. The DNA replication machinery is not able to replicate fully the DNA at the very end of the chromosomes; therefore, about 50-200 nucleotides are lost during each of the replication cycles resulting in a gradual decrease of telomere length. Critically short telomere induces senescence, subsequent crisis and cell death. In tumor cells, however, the telomerase enzyme prevents the formation of critically short telomeres, adding GGTTAG repeats to the 3' end of the chromosomes immortalizing the cells. Immortality is one of the hallmarks of cancer. Besides the catalytic activity dependent telomere maintenance, catalytic activity-independent effects of telomerase may also be involved in the regulation of cell cycle. The telomere/telomerase system offers two possibilities to intervene the proliferative activity of the cell: (1) inhibition the telomere maintenance by inhibiting the telomerase activity; (2) activating the residual telomerase enzyme or inducing telomerase expression. Whilst the former approach could abolish the limitless replicative potential of malignant cells, the activation of telomerase might be utilized for treating degenerative diseases. Here, we review the current status of telomerase therapeutics, summarizing the activities of those pharmacological agents which either inhibit or activate the enzyme. We also discuss the future opportunities and challenges of research on pharmacological intervention of telomerase activity.